Trimethylaminuria (TMAU) Cell Models for Research

Trimethylaminuria (TMAU), also known as fish odor syndrome, is a rare metabolic disorder characterized by the excessive excretion of trimethylamine (TMA) in breath, sweat, and urine, leading to a fishy odor. The exact prevalence is unknown, but it is estimated to affect 1 in 40,000 individuals, though many cases may be undiagnosed. TMAU is not life-threatening but can cause significant psychosocial distress, leading to depression, anxiety, and social isolation. There is no cure; management focuses on dietary restrictions (avoiding choline-rich foods) and antibiotics to reduce gut flora. The disease is caused by mutations in the FMO3 gene, which encodes flavin-containing monooxygenase 3, the enzyme responsible for oxidizing TMA to the non-odorous trimethylamine N-oxide (TMAO). Research is crucial to understand the molecular basis of FMO3 dysfunction and develop therapeutic strategies.

TMAU serves as an excellent model for studying enzyme function, genetic variation, and metabolic pathways. The FMO3 gene is part of the flavin-containing monooxygenase family, which plays a role in drug metabolism. Understanding FMO3 mutations can provide insights into inter-individual variability in drug response. Additionally, TMAU research can shed light on the gut-microbiome-host interaction, as TMA is produced by gut bacteria from dietary precursors. Gene-edited cell models, such as FMO3 knockout and knock-in lines, allow researchers to study the functional consequences of specific mutations in a controlled environment. These models are valuable for drug screening, functional genomics, and personalized medicine approaches.

Trimethylaminuria is not a cancer, but the underlying metabolic pathway is relevant to drug metabolism and toxicity. The primary pathway involves the conversion of dietary choline, carnitine, and lecithin to TMA by gut bacteria. TMA is then absorbed and oxidized by FMO3 in the liver to TMAO. Mutations in FMO3 impair this oxidation, leading to TMA accumulation. The pathway steps are:

1. Dietary precursors (choline, carnitine) are metabolized by gut microbiota to produce TMA.

2. TMA is absorbed into the bloodstream and transported to the liver.

3. In hepatocytes, FMO3 catalyzes the N-oxidation of TMA to TMAO.

4. TMAO is excreted in urine; if FMO3 is defective, TMA accumulates and is released in sweat, breath, and urine.

This pathway is also implicated in cardiovascular disease, as elevated TMAO levels are associated with increased risk. Thus, studying FMO3 function has broader implications.

Data from ClinVar and NCBI Gene. The most common mutations include c.458C>T (p.Pro153Leu) and c.472G>A (p.Glu158Lys), which are prevalent in populations with TMAU.

While TMAU is not a cancer, FMO3 activity influences metabolic signaling. Key points:

• • FMO3 is a phase I drug-metabolizing enzyme, affecting the metabolism of xenobiotics and endogenous compounds.
• • FMO3 expression is regulated by nuclear receptors such as PXR and CAR, which are involved in detoxification pathways.
• • Altered FMO3 activity can affect lipid metabolism, as TMAO has been linked to cholesterol and bile acid metabolism.
• • The gut-liver axis is critical: gut microbiota composition influences TMA production, and FMO3 activity modulates TMAO levels, impacting cardiovascular risk.

Gene-edited cell models can help dissect these interactions.

Organoids derived from liver or intestinal tissue can recapitulate gut-liver interactions, providing a more physiologically relevant model for studying TMA metabolism. However, gene-edited cell lines remain the workhorse for high-throughput studies.

• • FMO3 knockout mice: These mice exhibit elevated TMA levels and a fishy odor, mimicking TMAU. They are useful for studying the physiological consequences of FMO3 deficiency.
• • Transgenic mice expressing human FMO3 variants: These can be used to assess the impact of specific mutations on enzyme activity.
• • Gut microbiota manipulation: Germ-free mice or antibiotic-treated mice can be used to study the role of gut bacteria in TMA production.
• • PDX models are less relevant for TMAU, as it is not a cancer.

CRISPR-Cas9 gene editing allows the creation of isogenic cell lines with specific FMO3 mutations. For example:

• • FMO3 knockout cell lines: Complete loss of function, mimicking severe TMAU.
• • FMO3 knock-in cell lines: Introduction of specific patient mutations (e.g., p.Pro153Leu) to study their effect on enzyme activity.
• • Reporter cell lines: FMO3 promoter-driven fluorescent reporters to monitor gene expression.

These models are commercially available from various sources, ensuring sequence verification and quality control. They enable researchers to study the molecular consequences of FMO3 mutations, screen for potential therapeutic compounds, and investigate gene-environment interactions.

Gene-edited cell lines are essential for functional genomics studies. For example:

• • FMO3 knockout lines can be used to identify downstream metabolic changes via metabolomics.
• • Knock-in lines with specific mutations allow genotype-phenotype correlations.
• • CRISPR screens can identify genes that modulate FMO3 activity or compensate for its loss.

These approaches help elucidate the molecular basis of TMAU and identify potential therapeutic targets.

Isogenic cell pairs (wild-type vs. FMO3 knockout) are valuable for drug screening. They can be used to:

• • Test compounds that enhance FMO3 activity or bypass the defect.
• • Assess drug metabolism and toxicity in the context of FMO3 deficiency.
• • Model drug-induced TMAU, as some drugs inhibit FMO3.

This is crucial for developing personalized treatment strategies.

CRISPR-based synthetic lethality screens can identify genes that, when silenced, kill FMO3-deficient cells but not wild-type cells. This could reveal novel therapeutic targets. Additionally, gene-edited cells can be used to discover biomarkers for TMAU severity or response to treatment.